Patents by Inventor Jochen Springer

Jochen Springer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
    Patent number: 11938102
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: March 26, 2024
    Assignee: ACTIMED THERAPEUTICS LIMITED
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • Oxprenolol compositions for treating cancer
    Patent number: 11433036
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: September 6, 2022
    Assignee: Actimed Therapeutics Limited
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
    Publication number: 20210330615
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 15, 2021
    Publication date: October 28, 2021
    Inventors: Andrew J.S. COATS, Stefan ANKER, Jochen SPRINGER
  • OXPRENOLOL COMPOSITIONS FOR TREATING CANCER
    Publication number: 20210251924
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Application
    Filed: October 7, 2020
    Publication date: August 19, 2021
    Inventors: Andrew J.S. Coats, Stefan Anker, Jochen Springer
  • S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
    Patent number: 11007158
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: May 18, 2021
    Assignee: ACTIMED THERAPEUTICS LIMITED
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • Oxprenolol compositions for treating cancer
    Patent number: 10828270
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: November 10, 2020
    Assignee: Actimed Therapeutics Limited
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
    Publication number: 20200054585
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 20, 2020
    Inventors: Andrew J.S. COATS, Stefan ANKER, Jochen SPRINGER
  • S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
    Patent number: 10449166
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 22, 2019
    Assignee: ACTIMED THERAPEUTICS LTD
    Inventors: Andrew J. S. Coats, Stefan Anker, Jochen Springer
  • Oxprenolol compositions for treating cancer
    Patent number: 10398658
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 3, 2019
    Assignee: Actimed Therapeutics Limited
    Inventors: Andrew J.S. Coats, Stefan Anker, Jochen Springer
  • OXPRENOLOL COMPOSITIONS FOR TREATING CANCER
    Publication number: 20190054043
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Application
    Filed: March 16, 2018
    Publication date: February 21, 2019
    Inventors: Andrew J.S. Coats, Stefan Anker, Jochen Springer
  • Selective AT2 receptor agonists for use in treatment of cachexia
    Patent number: 10016397
    Abstract: The present invention is directed to selective AT2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: July 10, 2018
    Assignee: CHARITÉ—UNIVERSITAETSMEDIZN BERLIN
    Inventors: Jochen Springer, Stefan Anker, Andrew JS Coats
  • SELECTIVE AT2 RECEPTOR AGONISTS FOR USE IN TREATMENT OF CACHEXIA
    Publication number: 20160175286
    Abstract: The present invention is directed to selective AT2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 23, 2016
    Inventors: Jochen Springer, Stefan Anker, Andrew JS Coats
  • OXPRENOLOL COMPOSITIONS FOR TREATING CANCER
    Publication number: 20160022612
    Abstract: The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Andrew J.S. Coats, Stefan Anker, Jochen Springer
  • S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
    Publication number: 20160022613
    Abstract: The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Andrew J.S. COATS, Stefan ANKER, Jochen SPRINGER
  • Prevention and treatment of sarcopenia
    Patent number: 8835485
    Abstract: The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: September 16, 2014
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Jochen Springer, Stefan Anker, Andrew Coats, John Beadle
  • PREVENTION AND TREATMENT OF SARCOPENIA
    Publication number: 20120095070
    Abstract: The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.
    Type: Application
    Filed: April 29, 2010
    Publication date: April 19, 2012
    Applicant: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Jochen Springer, Stefan Anker, Andrew Coats, John Beadle
  • Use of Megestrol Acetate for the Treatment of Obstructive Pulmonary Diseases
    Publication number: 20080269179
    Abstract: The present invention relates to the treatment of patients suffering from pulmonary diseases, in particular from chronic obstructive pulmonary disease (COPD), bronchial asthma, cystic fibrosis and chronic cough in particular as caused by ACE-Inhibitors using megestrol acetate.
    Type: Application
    Filed: May 24, 2006
    Publication date: October 30, 2008
    Inventors: Stefan Anker, Jochen Springer